Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene Expression-Reference-Cited by-同舟云学术

Enhancement of the Behavioral Response to Apomorphine Administration Following Repeated Treatment in the 6-Hydroxydopamine-Lesioned Rat Is Temporally Correlated with a Rise in Striatal Preproenkephalin-B, but Not Preproenkephalin-A, Gene Expression

Published:1997-04 Issue:2 Volume:144 Page:423-432
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Duty Susan,Brotchie Jonathan M.

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference44 articles.

1. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens;Angulo;Brain. Res. Rev.,1994

2. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity;Bevan;Neurosci. Letts.,1983

3. Differential processing of proenkephalin by prohormone convertases 1(3) and 2 and furin;Breslin;J. Biol. Chem.,1993

4. D-[314;Brotchie;Exp. Neurol.,1991

5. The role of opioid peptides in the neural mechanisms underlying L-DOPA-induced dyskinesias in Parkinson's disease;Brotchie;Soc. Neurosci.,1995

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential effects of opioid receptor antagonism on the anti-dyskinetic and anti-parkinsonian effects of sub-anesthetic ketamine treatment in a preclinical model;Neuropharmacology;2024-10

2. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies;Brain Research Bulletin;2021-03

3. Classic animal models of Parkinson’s disease: a historical perspective;Behavioural Pharmacology;2019-06

4. The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia;Neuropharmacology;2018-10

5. The Opioid System in Levodopa-Induced Dyskinesia;Levodopa-Induced Dyskinesia in Parkinson's Disease;2014